IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions

Journal of Investigative Dermatology

Volumn 133, Issue 2, 2013, Pages 479-488

  Shibata, Sayaka ^a   Tada, Yayoi ^a   Asano, Yoshihide ^a   Yanaba, Koichi ^a   Sugaya, Makoto ^a   Kadono, Takafumi ^a   Kanda, Naoko ^b   Watanabe, Shinichi ^b   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BESELNA CREAM; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMIQUIMOD; INTERLEUKIN 27; MESSENGER RNA; PHOSPHATE BUFFERED SALINE; RECOMBINANT INTERLEUKIN 27; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DERMATITIS; DERMIS; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; RECEPTOR UPREGULATION; SKIN; SKIN DEFECT; TH1 CELL;

EID: 84872600320     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.313     Document Type: Article

References (35)

1. Amadi-Obi A, Yu CR, Liu X et al. (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13:711-8
2. Arican O, Aral M, Sasmaz S et al. (2005) Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005:273-9
3. Austin LM, Ozawa M, Kikuchi T et al. (1999) The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113:752-9
4. Batten M, Ghilardi N (2007) The biology and therapeutic potential of interleukin 27. J Mol Med 85:661-72
5. Batten M, Li J, Yi S et al. (2006) Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 7:929-36
6. Bonifati C, Ameglio F (1999) Cytokines in psoriasis. Int J Dermatol 38:241-51
7. Cai Y, Shen X, Ding C et al. (2011) Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 35:596-610
8. Cao Y, Doodes PD, Glant TT et al. (2008) IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol 180:922-30
9. Diveu C, McGeachy MJ, Cua DJ (2008) Cytokines that regulate autoimmunity. Curr Opin Immunol 20:663-8
10. Fitzgerald DC, Ciric B, Touil T et al. (2007) Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 179:3268-75
11. Flier J, Boorsma DM, Bruynzeel DP et al. (1999) The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. J Invest Dermatol 113:574-8
12. Flier J, Boorsma DM, van Beek PJ et al. (2001) Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 194:398-405
13. Giustizieri ML, Mascia F, Frezzolini A et al. (2001) Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 107:871-7
14. Gottlieb AB, Luster AD, Posnett DN et al. (1988) Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J Exper Med 168: 941-8
15. Guenther LC, Ortonne JP (2002) Pathophysiology of psoriasis: science behind therapy. J Cutaneous Med Surg 6:2-7
16. Honda K, Nakamura K, Matsui N et al. (2005) T helper 1-inducing property of IL-27/WSX-1 signaling is required for the induction of experimental colitis. Inflamm Bowel Dis 11:1044-52
17. Ishizaki M, Akimoto T, Muromoto R et al. (2011) Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol 187:181-9
18. Iwamoto S, Iwai S, Tsujiyama K et al. (2007) TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol 179:1449-57
19. Kastelein RA, Hunter CA, Cua DJ (2007) Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 25:221-42
20. Li J, Zhao Q, Xing W et al. (2011) Interleukin-27 enhances the production of tumour necrosis factor-alpha and interferon-gamma by bone marrow T lymphocytes in aplastic anaemia. Br J Haematol 153:764-72
21. Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866-73
22. Nestle FO, Conrad C, Tun-Kyi A et al. (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exper Med 202:135-43
23. Niedbala W, Cai B, Wei X et al. (2008) Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis 67:1474-9
24. Owaki T, Asakawa M, Morishima N et al. (2005) A role for IL-27 in early regulation of Th1 differentiation. J Immunol 175:2191-200
25. Prinz JC (2003) The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 17:257-70
26. Schmidt C, Giese T, Ludwig B et al. (2005) Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11:16-23
27. Shibata S, Tada Y, Kanda N et al. (2010) Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol 130:1034-9
28. Stumhofer JS, Hunter CA (2008) Advances in understanding the anti-inflammatory properties of IL-27. Immunol Lett 117:123-30
29. Szegedi A, Aleksza M, Gonda A et al. (2003) Elevated rate of Thelper1 (T(H)1) lymphocytes and serum IFN-gamma levels in psoriatic patients. Immunol Lett 86:277-80
30. Takeda A, Hamano S, Yamanaka A et al. (2003) Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 170:4886-90
31. Van Belle AB, de Heusch M, Lemaire MM et al. (2012) IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 188:462-9
32. van der Fits L, Mourits S, Voerman JS et al. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182:5836-45
33. Wittmann M, Zeitvogel J, Wang D et al. (2009) IL-27 is expressed in chronic human eczematous skin lesions and stimulates human keratinocytes. J Allergy Clin Immunol 124:81-9
34. Yoshimura T, Takeda A, Hamano S et al. (2006) Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol 177:5377-85
35. Zaba LC, Cardinale I, Gilleaudeau P et al. (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exper Med 204:3183-94